Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis | Zendy

Charlotte Gran | Zendy; Johanna Borg Bruchfeld | Zendy; Fredrik Ellin | Zendy; Hareth Nahi | Zendy

Open Access

Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis

Author(s) -

Charlotte Gran,

Johanna Borg Bruchfeld,

Fredrik Ellin,

Hareth Nahi

Publication year - 2020

Publication title -

acta haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.574

H-Index - 56

eISSN - 1421-9662

pISSN - 0001-5792

DOI - 10.1159/000504355

Subject(s) - venetoclax , al amyloidosis , immunoglobulin light chain , refractory (planetary science) , medicine , antibody , amyloidosis , immunology , pathology , chronic lymphocytic leukemia , leukemia , biology , astrobiology

Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research